Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3226976#aggregation> ?p ?o. }
Showing items 1 to 40 of
40
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B604281.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2012".
- aggregation format "application/pdf".
- aggregation hasFormat 3226976.bibtex.
- aggregation hasFormat 3226976.csv.
- aggregation hasFormat 3226976.dc.
- aggregation hasFormat 3226976.didl.
- aggregation hasFormat 3226976.doc.
- aggregation hasFormat 3226976.json.
- aggregation hasFormat 3226976.mets.
- aggregation hasFormat 3226976.mods.
- aggregation hasFormat 3226976.rdf.
- aggregation hasFormat 3226976.ris.
- aggregation hasFormat 3226976.txt.
- aggregation hasFormat 3226976.xls.
- aggregation hasFormat 3226976.yaml.
- aggregation isPartOf urn:issn:1535-3508.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model".
- aggregation abstract "As apoptosis occurs over an interval of time after administration of apoptosis-inducing therapy in tumors, the changes in technetium 99m (Tc-99m)-tricarbonyl (CO)(3) His-annexin A5 (His-ann A5) accumulation over time were examined. Colo205-bearing mice were divided into six treatment groups: (1) control, (2) 5-fluorouracil (5-FU; 250 mg/kg), (3) irinotecan (100 mg/kg), (4) oxaliplatin (30 mg/kg), (5) bevacizumab (5 mg/kg), and (6) panitumumab (6 mg/kg). (99)mTc-(CO)(3) His-ann A5 was injected 4, 8, 12, 24, and 48 hours posttreatment, and micro-single-photon emission computed tomography was performed. Immunostaining of caspase-3 (apoptosis), survivin (antiapoptosis), and LC3-II (autophagy marker) was also performed. Different dynamics of (99)mTc-(CO)(3) His-ann A5 uptake were observed in this colorectal cancer xenograft model, in response to a single dose of three different chemotherapeutics (5-FU, irinotecan, and oxaliplatin). Bevacizumab-treated mice showed no increased uptake of the radiotracer, and a peak of (99)mTc-(CO)(3) HisannA5 uptake in panitumumab-treated mice was observed 24 hours posttreatment, as confirmed by caspase-3 immunostaining. For irinotecan-, oxaliplatin-, and bevacizumab-treated tumors, a significant correlation was established between the radiotracer uptake and caspase-3 immunostaining (r = .8, p < .05; r = .9, p < .001; r = .9, p < .001, respectively). For 5-FU- and panitumumab-treated mice, the correlation coefficients were r = .7 (p = .18) and r = .7 (p = .19), respectively. Optimal timing of annexin A5 imaging after the start of different treatments in the Colo205 model was determined.".
- aggregation authorList BK959393.
- aggregation endPage "147".
- aggregation issue "2".
- aggregation startPage "135".
- aggregation volume "11".
- aggregation aggregates 3227203.
- aggregation isDescribedBy 3226976.
- aggregation similarTo 7290.2011.00034.
- aggregation similarTo LU-3226976.